A Crucial Enhancement to the Takahashi and Alexander’s Cash Flow Model
The Journal of Private Markets Investing · 2026
DOI: 10.3905/jpmi.2026.1.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Private Markets Investing, 2026. Verfasst von Vishv Jeet und 2 weiteren Autor:innen.
Abstract (Originalsprache)
The Takahashi–Alexander (TA) model is a widely used framework for simulating private equity cash flows. However, its core shape parameter b, which governs distribution timing, lacks a direct connection to investor-relevant metrics such as internal rate of return (IRR) and total value to paid-in capital (TVPI). This article introduces a reformulation of the TA model that replaces the opaque b-parameter with a more intuitive and analytically derived function of the investor’s performance goals. We define a dimensionless duration fraction , where M is the desired TVPI, G the target IRR, and L the fund’s life. We then derive the relationship , offering a closed-form link between fund performance objectives and the TA model’s cash flow shape. This formulation simplifies calibration, enhances interpretability, and enables goal-driven simulation of capital calls and distributions. Numerical validation confirms the robustness of the approximation across a wide range of practical scenarios, making the TA model significantly more accessible and aligned with real-world decision-making.
Zitieren
APA
Jeet, V., Stucke, R. R., & Partani, A. (2026). A Crucial Enhancement to the Takahashi and Alexander’s Cash Flow Model. The Journal of Private Markets Investing. https://doi.org/10.3905/jpmi.2026.1.010
Vancouver
Jeet V, Stucke RR, Partani A. A Crucial Enhancement to the Takahashi and Alexander’s Cash Flow Model. The Journal of Private Markets Investing. 2026. doi:10.3905/jpmi.2026.1.010
BibTeX
@article{Jeet2026,
author = {Jeet, Vishv and Stucke, Rüediger R. and Partani, Amit},
title = {A Crucial Enhancement to the Takahashi and Alexander’s Cash Flow Model},
journal = {The Journal of Private Markets Investing},
year = {2026},
doi = {10.3905/jpmi.2026.1.010}
}
EUVIMED